FIELD: chemistry.
SUBSTANCE: invention relates to novel 2-ethyl-6-methyl-3-hydroxypyridine orotate dihydrate salt and a method for production thereof. 2-Ethyl-6-methyl-3-hydroxypyridine orotate dihydrate corresponds to formula C8H11NO⋅C5H4N2O4⋅2H2O. 2-Ethyl-6-methyl-3-hydroxypyridine orotate dihydrate can be used to produce a pharmaceutical composition for preventing and/or treating hypoxia, including 2-ethyl-6-methyl-3-hydroxypyridine orotate and a pharmaceutically acceptable carrier. Method of producing orotate involves A) 2-ethyl-6-methyl-3-hydroxypyridine (1000.0 mg) is dissolved in isopropyl alcohol (5 ml) at room temperature; B) orotic acid 56.9 mg (0.000364479 mol) is dissolved in 5 ml of a mixture of acetonitrile / water (1:1) at temperature of 80 °C; B) and adding 250 mcl of solution of 2-ethyl-6-methyl-3-hydroxypyridine (0.000364479 mole) obtained above; D) obtained mixture is cooled to room temperature naturally, precipitate is released 20–30 minutes after preparation. Product is obtained in form of a monocrystal. According to thermogravimetry and X-ray structural analysis, 2-ethyl-6-methyl-3-hydroxypyridine monochloride orotate dihydrate has an endothermic peak of 90–115 °C according to differential scanning calorimetry and peaks measurement data 2Θ° 8.1, 9.1, 10.0, 12.5, 12.9, 13.9, 15.2, 15.5, 18.0, 19.4, 19.6, 21.6, 22.1, 25.5, 28.7, 29.8, 30.4, 32.3 on X-ray diffraction measurements.
EFFECT: compound can be used as a antihypoxic agent for preventing or treating cardiovascular diseases, including atherosclerosis, myocardial dystrophy, anemia, IHD, including angina pectoris, myocardial infarction, chronic cardiac failure and heart rhythm disturbances, including magnesium-dependent arrhythmia, atrial fibrillation, or as an adjunct to liver diseases, including hepatitis, hepatosis and bile ducts caused by acute and chronic intoxication, except for organic damages of liver and bile ducts.
8 cl, 6 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
SALICYLATE OF 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE, SOLVATES AND HYDRATES AND METHOD FOR PRODUCING THEREOF | 2017 |
|
RU2652891C1 |
ASPIRINATE-2-ETHYL-6-METHYL-3-HYDROXIPIRIDINE THAT IS ANTOHYPOXIC AND WAY OF ITS PRODUCTION | 2010 |
|
RU2442774C1 |
ALISKIREN AND OROTIC ACID SALT | 2007 |
|
RU2456267C2 |
NOVEL 3-HYDROXYPYRIDINE DERIVATIVE HAVING LIPID REGULATING ACTIVITY | 2020 |
|
RU2743923C1 |
STABLE LIQUID PHARMACEUTICAL COMPOSITION OF 3-(2,2,2-TRIMETHYLHYDRAZINIUM) PROPIONATE-2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE DISUCCINATE COMPLEX, HAVING ANTIHYPOXIC, ANTIOXIDANT AND ADAPTOGENIC ACTION | 2013 |
|
RU2527347C1 |
DOSAGE FORM FOR INJECTION IN FORM OF SOLUTION AND STABILIZER FOR ITS PREPARATION | 2020 |
|
RU2755094C1 |
USE OF A PHARMACEUTICAL COMPOSITION WITH ANTIOXIDANT, VIRUCIDAL, IMMUNOSTULATING, ANTIHYPOXIC AND ANTI-AGGREGANT EFFECT | 2023 |
|
RU2808445C1 |
PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CARDIOVASCULAR DISEASES | 2011 |
|
RU2491070C2 |
NOVEL COMPOSITIONS AND METHODS OF PRODUCING 5-AMINO- OR SUBSTITUTED AMINO-1,2,3-TRIAZOLES AND TRIAZOLE-OROTATE COMPOSITIONS | 2010 |
|
RU2594155C2 |
SYNERGETIC PREPARATION FOR TREATING CARDIOVASCULAR DISEASES, DIABETES MELLITUS AND HEPATOBILIARY DISEASES | 2012 |
|
RU2493841C1 |
Authors
Dates
2019-06-05—Published
2017-05-04—Filed